Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naltrexone controlled-release - Alkermes

Drug Profile

Naltrexone controlled-release - Alkermes

Alternative Names: ALKS 6428; Vivitrex; Vivitrol; XL-NTX; XR-NTX

Latest Information Update: 05 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alkermes
  • Developer Alkermes; Alkermes plc; Cephalon; Cilag GmbH International; University of Oslo
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Alcoholism; Opioid-related disorders

Most Recent Events

  • 05 Jan 2024 Discontinued - Phase-III for Opioid-related disorders in Norway (IM) (Alkermes pipeline; January 2024)
  • 08 Feb 2022 Alkermes terminates phase II trial in Substance-related disorders (Prevention) in Sweden (EudraCT2016-004710-95)
  • 24 Feb 2021 No development reported - Phase-III for Opioid-related disorders in Norway (IM)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top